FCM
BHVN

Farallon Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Farallon Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,947,820
Closed -$294M – 323
2022
Q3 		$294M Hold
1,947,820
– – 1.62% 22
2022
Q2 		$284M Buy
+1,947,820
New +$249M 1.54% 25

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Farallon Capital Management's BHVN Position: Q4 2022 in Review

Farallon Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,947,820 shares — an estimated $294M sold.

Farallon Capital Management first reported a position in BHVN in Q2 2022 and held it in 2 quarters. The position peaked at $294M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Farallon Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Farallon Capital Management sold 1,947,820 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $294M.
  • Farallon Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 2 quarters.
  • Farallon Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $294M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.